Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Isa-KRd Significantly Improves MRD Negativity Rates at Cutoffs Vs KRd in Newly Diagnosed Multiple Myeloma

December 11th 2023

The combination of Isa-KRd significantly increased the rates of minimal residual disease negativity at cutoffs post-consolidation vs KRd in patients with newly diagnosed multiple myeloma.

Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma

December 10th 2023

Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.

Ultrasensitive BCMA CARs Deliver Responses With Tolerable Safety in R/R Multiple Myeloma

December 10th 2023

The use of the BCMA-directed CAR T-cell therapy D8 Fab CAR and the dual-targeting AUTO8 CAR T-cell therapy is safe and feasible in patients with relapsed/refractory multiple myeloma.

Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma

December 9th 2023

Idecabtagene vicleucel resulted in meaningful improvements in symptoms, functioning, overall health status, and health-related quality of life vs standard regimens in select patients with triple-class exposed relapsed/refractory multiple myeloma, according to updated data from the phase 3 KarMMa-3 trial.

Dr Braunstein on the Evolution of ASCT in Multiple Myeloma

November 29th 2023

Marc J. Braunstein, MD, PhD, discusses the evolution of autologous stem cell transplantation and ongoing treatment needed to better determine when ASCT should be recommended for patients with multiple myeloma.

Belantamab Mafodotin Plus Bortezomib/Dexamethasone Improves PFS in R/R Multiple Myeloma

November 27th 2023

Belantamab mafodotin plus bortezomib and dexamethasone significantly improved progression-free survival compared with daratumumab plus B-Vd in the second-line treatment of patients with relapsed or refractory multiple myeloma, meeting the primary end point of the phase 3 DREAMM-7 trial.

Ongoing Research Aims to Better Define Role of ASCT in Myeloma

November 27th 2023

Marc J. Braunstein, MD, PhD, discusses the current role of autologous stem cell transplant for patients with multiple myeloma, highlighted the key factors used to determine patient eligibility, and detailed ongoing research centered around autologous stem cell transplant.

Dr Davies on Addressing Global Gaps in Multiple Myeloma Care

November 22nd 2023

Faith E. Davies, MD, discusses strategies for rectifying global gaps and addressing unmet needs in multiple myeloma care.

Dr Richter on the Current State of Bispecific Antibodies in Multiple Myeloma

November 21st 2023

Joshua Richter, MD, discusses how bispecific antibodies fit into the current treatment armamentarium for patients with multiple myeloma, highlighting his presentation from the 41st Annual CFS®.

Ongoing Research Aims to Bring Bispecific Antibodies to Earlier Settings and Novel Combinations in Myeloma

November 21st 2023

Joshua Richter, MD, provides an overview of the current state of bispecific antibodies in multiple myeloma, discusses ongoing investigations of these agents, and expands on their unique toxicities and the need for proactive management.

FDA’s ODAC to Review Data for Ide-Cel in Triple-Class Exposed R/R Myeloma

November 20th 2023

The FDA’s Oncologic Drugs Advisory Committee will meet to review data from the supplemental biologics license application seeking the approval of idecabtagene vicleucel for use in earlier lines of treatment for patients with triple-class exposed relapsed/refractory multiple myeloma.

Dr Braunstein on Stem Cell Transplant Eligibility Criteria in Multiple Myeloma

November 9th 2023

Marc J. Braunstein, MD, PhD, discusses the evolution of stem cell transplant eligibility criteria in patients with multiple myeloma and highlights unanswered questions about the role of autologous stem cell transplantation following quadruplet induction regimens in this population.

Dr Berdeja on the Current Role of BCMA-Targeted Therapies in Multiple Myeloma

November 8th 2023

Jesus Berdeja, MD, discusses the current role of BCMA-targeted therapies in multiple myeloma, and imparts advice to colleagues regarding the sequencing of bispecific antibodies and CAR T-cell therapies.

BCMA-Directed Therapies Broaden Myeloma Arsenal and Could Reshape Earlier Lines of Treatment

November 6th 2023

Jesus Berdeja, MD, discussed considerations when choosing between bispecific antibodies and CAR T-cell therapy for patients with multiple myeloma, clinical trials that may move CAR T-cell therapy into earlier lines, and research with agents directed at targets other than BCMA.

Elranatamab Approaches EU Approval for Heavily Pretreated Relapsed/Refractory Multiple Myeloma

November 1st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of elranatamab-bcmm for the treatment of adult patients with relapsed/refractory multiple myeloma who were previously treated with 3 or more lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, and who experienced disease progression on their last therapy.

Dr Dhodapkar on the Role of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

October 30th 2023

Madhav V. Dhodapkar, MBBS, discusses the advantages and disadvantages of bispecific antibodies and CAR T-cell therapy in patients with relapsed/refractory multiple myeloma, as well as the potential role for the bispecific antibody linvoseltamab in this treatment paradigm.

Dr Berdeja on Ongoing and Planned Research Initiatives in Patients With Multiple Myeloma

October 26th 2023

Jesus Berdeja, MD, director, discusses ongoing and planned research initiatives in patients with multiple myeloma, specifically highlighting initiatives taking place at Tennessee Oncology.

Dr Berdeja on the Evolving Use of CAR T-Cell Therapy in Multiple Myeloma

October 23rd 2023

Jesus Berdeja, MD, director, discusses the evolving guidelines regarding the use of CAR T-cell therapy in patients with multiple myeloma.

Dr Lin on Findings From the CARTITUDE-1 Trial in Relapsed/Refractory Multiple Myeloma

October 19th 2023

Yi Lin, MD, PhD, discusses findings from the primary analysis of the phase 1/2 CARTITUDE-1 trial of the BCMA-targeting CAR T-cell therapy ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Dr Berdeja on Patient Factors That Drive Treatment Decisions in Multiple Myeloma

October 18th 2023

Jesus Berdeja, MD, discusses factors to consider when choosing between CAR T-cell therapy and bispecific antibodies in patients with multiple myeloma.